zoledronic acid has been researched along with Kidney Failure in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (31.58) | 29.6817 |
| 2010's | 10 (52.63) | 24.3611 |
| 2020's | 3 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Barbary, R; Cameron, M; Sahota, A; Sahota, O; Stewart, AM | 1 |
| Bourlon, C; Bourlon, MT; Carretero-Gonzalez, A; Carril-Ajuria, L; Castellano, D; de Velasco, G; Martin-Soberon, M; Remolina-Bonilla, YA | 1 |
| Ntanasis-Stathopoulos, I; Terpos, E | 1 |
| Choueiri, TK; Heng, DY; Lin, X; McKay, RR; Perkins, JJ; Simantov, R | 1 |
| Mizuki, M; Morio, K; Tsugane, M; Uejima, E | 1 |
| Bergner, R; Gretz, N; Kränzlin, B; Pohlmeyer-Esch, G; Siegrist, B | 1 |
| Abrams, K; Boonen, S; Eriksen, EF; Lippuner, K; Mesenbrink, P; Miller, PD; Orlov-Morozov, A; Sellmeyer, DE | 1 |
| Antràs, L; Diel, IJ; Duh, MS; Green, J; Köppler, H; Neary, M; Smith, M; Weide, R; Wintfeld, N | 1 |
| Grieve, RJ; Hamilton, E; Hickish, T; Houston, S; Percival, F | 1 |
| Arnold, RM; Weinstein, E | 1 |
| Ludwig, H; Zojer, N | 1 |
| Dore, RK | 1 |
| Beuzeboc, P; Deray, G; Gligorov, J; Janus, N; Launay-Vacher, V; Le Tourneau, C; Ray-Coquard, I; Spano, JP | 1 |
| Morgan, G | 1 |
| Cha, YJ; Lee, YJ | 1 |
| D'Agati, VD; Fine, PL; Hoh, S; Kunis, CL; Markowitz, GS; Nasr, SH; Palecki, W; Park, J; Radhakrishnan, J; Siegel, DS; Stack, JI | 1 |
| Beitz, J; Chang, JT; Green, L | 1 |
| Antràs, L; Daskivich, T; Duh, MS; Evan, C; Nakabayashi, M; Neary, MP; Oh, WK; Proctor, K; Smith, M; Tormey, LK | 1 |
| Chang, JT | 1 |
2 review(s) available for zoledronic acid and Kidney Failure
| Article | Year |
|---|---|
Controversies in the use of new bone-modifying therapies in multiple myeloma.
Topics: Bone Density Conservation Agents; COVID-19; Denosumab; Diphosphonates; Humans; Hypercalcemia; Multiple Myeloma; Osteolysis; Receptor Activator of Nuclear Factor-kappa B; Renal Insufficiency; Zoledronic Acid | 2021 |
Supportive therapy in multiple myeloma.
Topics: Anemia; Blood Transfusion; Bone Diseases; Calcitonin; Clodronic Acid; Diphosphonates; Erythropoietin; Fractures, Bone; Hematinics; Humans; Hypercalcemia; Imidazoles; Multiple Myeloma; Osteoporosis; Pamidronate; Recombinant Proteins; Renal Insufficiency; Zoledronic Acid | 2011 |
1 trial(s) available for zoledronic acid and Kidney Failure
| Article | Year |
|---|---|
Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Cohort Studies; Creatinine; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Kidney; Middle Aged; Osteoporosis, Postmenopausal; Renal Insufficiency; Safety; Time Factors; Zoledronic Acid | 2008 |
16 other study(ies) available for zoledronic acid and Kidney Failure
| Article | Year |
|---|---|
Safety of zoledronate in older patients at high risk of fracture with reduced renal function.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans; Kidney; Renal Insufficiency; Zoledronic Acid | 2022 |
Challenges of Treating a Patient With Advanced Prostate Cancer During the COVID-19 Pandemic.
Topics: Aged; Androgen Antagonists; Androstenes; Anticoagulants; Antineoplastic Agents; Betacoronavirus; Bone Density Conservation Agents; Bone Neoplasms; Cancer Pain; Coronavirus Infections; COVID-19; Disease Progression; Docetaxel; Drug Combinations; Eligibility Determination; Heparin, Low-Molecular-Weight; Humans; Intensive Care Units; Lopinavir; Male; Oxygen Inhalation Therapy; Palliative Care; Pandemics; Pneumonia, Viral; Prostatic Neoplasms, Castration-Resistant; Renal Insufficiency; Respiratory Insufficiency; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; SARS-CoV-2; Severity of Illness Index; Zoledronic Acid | 2020 |
Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Axitinib; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease-Free Survival; Female; Humans; Hypocalcemia; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Pamidronate; Phenylurea Compounds; Prognosis; Pyrroles; Renal Insufficiency; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2014 |
[Effect of the administration of zoledronic acid on life expectancy in patients with multiple myeloma with or without renal impairment].
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Life Expectancy; Male; Middle Aged; Multiple Myeloma; Renal Insufficiency; Retrospective Studies; Treatment Outcome; Zoledronic Acid | 2014 |
Nephrotoxicity of ibandronate and zoledronate in Wistar rats with normal renal function and after unilateral nephrectomy.
Topics: Animals; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Kidney; Nephrectomy; Rats; Rats, Wistar; Renal Insufficiency; Zoledronic Acid | 2015 |
Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Cancer Care Facilities; Creatinine; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Middle Aged; Multivariate Analysis; Neoplasms; Proportional Hazards Models; Renal Insufficiency; Retrospective Studies; Zoledronic Acid | 2009 |
Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Health Care Costs; Health Resources; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Kidney; Kidney Function Tests; Middle Aged; Renal Insufficiency; State Medicine; Zoledronic Acid | 2010 |
Bisphosphonates for bone pain #113.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Neoplasms; Pain; Pamidronate; Renal Insufficiency; Zoledronic Acid | 2010 |
Data from extension trials: denosumab and zoledronic acid.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Comorbidity; Contraindications; Creatinine; Denosumab; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; RANK Ligand; Renal Insufficiency; Treatment Outcome; Zoledronic Acid | 2012 |
[Renal insufficiency and breast cancer].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Creatinine; Dehydration; Diphosphonates; Female; Glomerular Filtration Rate; Humans; Imidazoles; Kidney; Middle Aged; Renal Insufficiency; Young Adult; Zoledronic Acid | 2012 |
Myeloma: diagnosis complications and supportive care.
Topics: Amyloidosis; Anemia; Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Boronic Acids; Bortezomib; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Pyrazines; Quality of Life; Renal Insufficiency; Thrombosis; Zoledronic Acid | 2012 |
Risk factors for renal impairment in patients with solid tumors or multiple myeloma treated with zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Contraindications; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Drug Monitoring; Female; Hospitals, Teaching; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasms; Practice Guidelines as Topic; Renal Insufficiency; Republic of Korea; Retrospective Studies; Risk Factors; Zoledronic Acid | 2013 |
Toxic acute tubular necrosis following treatment with zoledronate (Zometa).
Topics: Aged; Aged, 80 and over; Apoptosis; Biopsy; Cohort Studies; Diphosphonates; Female; Humans; Imidazoles; Kidney; Kidney Tubular Necrosis, Acute; Male; Middle Aged; Renal Insufficiency; Sodium-Potassium-Exchanging ATPase; Time Factors; Zoledronic Acid | 2003 |
Renal failure with the use of zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Renal Insufficiency; Zoledronic Acid | 2003 |
The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Renal Insufficiency; Retrospective Studies; Risk Factors; Zoledronic Acid | 2007 |
Yearly zoledronic acid in postmenopausal osteoporosis.
Topics: Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Imidazoles; Osteoporosis, Postmenopausal; Renal Insufficiency; Zoledronic Acid | 2007 |